FDA clears Cellenkos IND application for potential ALS treatment
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
List view / Grid view
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
The Chinese National Medical Products Administration has approved a Phase Ib study of Everest Medicines' EVER001, for potential treatment of glomerular diseases.
Silo Pharma says it is preparing a pre-IND package and meeting with the FDA for a topical formulation of ketamine to treat fibromyalgia.
Clarametyx says the FDA has accepted an IND application for first-in-human trials of CMTX-101, an antibody to treat bacterial pneumonia.
In this Q&A, Immunexpress Chief Executive Officer Dr Rolland Carlson and Chief Scientific Officer Dr Richard Brandon discuss key aspects for molecular diagnostic discovery and development platforms, including how to best leverage microarray and next-generation sequencing (NGS) tools.
In a recent study, scientists have highlighted the possible use of South Asian medicine, specifically, Ayurvedic medicine, to treat type 2 diabetes. In this article, Drug Target Review dives into the study’s implications and what it means for the western world of drug discovery.
Pre-clinical research from VBI Vaccines has demonstrated an encouraging ability to boost and broaden the immune response against the coronavirus Beta variant.
Scientists have developed a delivery method that enhances treatment by adding CAR T cells and specialising signalling proteins to a hydrogel that is injected next to a tumour.
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
Scientists have discovered the essential role of a ligand-dependent corepressor to potentially enable cancer cells to present tumour antigens on their surfaces.
New research has discovered metabolic mechanisms that contribute to how ovarian cancer escapes from immune attack and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
With operations in over 100 countries worldwide, GenScript Biotech, an industry leader in biotechnology reagent services, has established a new UK office in the Oxford area to better connect with the UK biosciences sector.
This study demonstrates the ease, simplicity and speed of performing multiple conditions in one experiment using Ambr 15 Cell Culture by assessing five different media compositions on two different clones.
The CRISPR-based therapy called EBT-101 excised HIV proviral DNA from the genomes of different cells and tissues in human cells and mice.
Scientists targeted a mouse's own cells using a synthetic molecule called EEZE, presenting a novel way to treat pneumonia.